Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
Open Access
- 6 June 2023
- journal article
- letter
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 43 (8) , 943-946
Abstract
No abstract availableFunding Information
- La Ligue Nationale Contre le Cancer (EL2022: FB)
This publication has 10 references indexed in Scilit:
- Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel AgentsCancers, 2022
- Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesCancer Cell, 2022
- Tertiary lymphoid structures in cancerScience, 2022
- The emerging role of immune checkpoint inhibitors for the treatment of breast cancerExpert Opinion on Investigational Drugs, 2021
- The 12-CK Score: Global Measurement of Tertiary Lymphoid StructuresFrontiers in Immunology, 2021
- Tertiary lymphoid structures in the era of cancer immunotherapyNature Reviews Cancer, 2019
- The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancerBritish Journal of Cancer, 2018
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeJournal of Clinical Investigation, 2017
- Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast CancerCancer Research and Treatment, 2017
- CD4+ follicular helper T cell infiltration predicts breast cancer survivalJournal of Clinical Investigation, 2013